Can you give an overview of your practice and your research interests?

I know the treatment paradigm for a multiple melanoma is pretty individualized at this stage. You have like IMiDs, proteasome inhibitors, CD38s. Can you kind of give us just an overviewon what treatment looks like from your end prior to any BCMA directed therapy?

Do you use selinexor or alkylating agents in late-late patients at all? If so, can you give me your opinions on them? (Bendamustine and Prednisone)

Can you discuss your experiences with BCMA targeted therapies and your opinions of them? Ocular toxicity is a concern with Blenrep? Supply issues with Ide-cel (lenti-viral vector)

The efficacy of ide-cel ->28% CR rate, 19 month median duration for these who achieved CR, 72% ORR. 
cilta-cel had sCR rate of about 83% in latest update with median duration not reached. In your mind isn't cilta-cel blatantly better than ide-cel? Is there any real reason you would ever use ide-cel if both were available?

cilta-cel also has a longer delay (7 days) to CRS, which makes it more amenable for outpatient administration and reimbursement. How important is that for you?

There are like over 10 BCMA CAR-Ts in development. Do you really see any room for differentiation between the auto CAR-Ts?

Teclistimab was filed earlier this year, how do you envision that being used? Do you think there are any really big differentiating points between the amgen, regeneron, pfizer, jnj bispecifics?

Do you see any situation where you would use multiple BCMA targeted therapies? Maybe as an example, Blenrep after ide-cel or cilta-cel failure?

There's some other ADCs in development, I think MedImmune has one. What are your opinions on ADCs as a modality in this indication? Sees like they might most be reserved as salvage therapies?

Any other modality in BCMA targeted therapies that interest you?

How meaningful will the approval of cilta-cel be for you as a clinician in the penta-refractory population?